'No preparedness planning, no accountability, no action plan'

'This government did not have any plan for safety stocks of essential medicines.' IMAGE: Doctors attend to a patient suffering from COVID-19 inside the emergency room at the Safdarjung Hospital in......

Govt waives import duty on Remdesivir

Amid surging COVID-19 cases in the country, the government on Tuesday waived customs duty on Remdesivir, its raw materials and other components used to make the antiviral drug. The move would help......

Syngene to enter drug discovery

Syngene, the contract research subsidiary of Biocon, India's leading biotechnology company, is going into a critical new area. It is making its first foray into drug discovery which will convert it......

'Tariffs will hurt insurance, patients and everyone'

'If people have to build new facilities, and by the time they are operational, it will be time for a new President in the US.' Photograph: Amit Dave/Reuters After registering a net profit of Rs......

'Expect formulations biz to outpace API biz'

'API prices are dragging down margins and impacting our competitive ability.' Photograph: Kind courtesy Biocon Biocon delves into the evolving dynamics of the biosimilar market, with a focus on......

'The formulations business been a growth driver'

'Fundamentally, we think that in the coming quarters, API business should come back.' Photograph: Kind courtesy Biocon Biocon is preparing to make the most of the peptides opportunity as these......